Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

161 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma.
Pond GR, Agarwal N, Bellmunt J, Choueiri TK, Qu A, Fougeray R, Vaughn D, James ND, Salhi Y, Albers P, Niegisch G, Galsky MD, Wong YN, Ko YJ, Stadler WM, O'Donnell PH, Sridhar SS, Vogelzang NJ, Necchi A, Di Lorenzo G, Sternberg CN, Mehta A, Sonpavde G. Pond GR, et al. Among authors: niegisch g. BJU Int. 2014 May;113(5b):E137-43. doi: 10.1111/bju.12564. BJU Int. 2014. PMID: 24219029
[Neutropenia - when is GCSF support indicated?].
Rehlinghaus M, Rehker P, Che Y, Grunewald CM, Niegisch G. Rehlinghaus M, et al. Among authors: niegisch g. Aktuelle Urol. 2024 Feb;55(1):38-43. doi: 10.1055/a-2128-4965. Epub 2023 Aug 22. Aktuelle Urol. 2024. PMID: 37607583 German.
BTA stat®, NMP22® BladderChek®, UBC® Rapid Test, and CancerCheck® UBC® rapid VISUAL as urinary marker for bladder cancer: Final results of a German multicenter study.
Ecke TH, Meisl CJ, Schlomm T Prof, Rabien A, Labonté F, Rong D, Hofbauer S, Friedersdorff F Prof, Sommerfeldt L, Gagel N, Gössl A, Barski D, Otto T Prof, Grunewald CM, Niegisch G Prof, Hennig MJP, Kramer MW Prof, Koch S Prof, Roggisch J, Hallmann S, Weiß S, Waldner M, Graff J, Veltrup E, Linden F, Hake R, Eidt S, Wirtz RM. Ecke TH, et al. Among authors: niegisch g prof. Urol Oncol. 2023 Dec;41(12):484.e17-484.e26. doi: 10.1016/j.urolonc.2023.06.013. Epub 2023 Jul 4. Urol Oncol. 2023. PMID: 37407421
Efficacy and safety outcomes of darolutamide in patients with non-metastatic castration-resistant prostate cancer with comorbidities and concomitant medications from the randomised phase 3 ARAMIS trial.
Fizazi K, Shore ND, Smith M, Ramos R, Jones R, Niegisch G, Vjaters E, Wang Y, Srinivasan S, Sarapohja T, Verholen F. Fizazi K, et al. Among authors: niegisch g. Eur J Cancer. 2023 Oct;192:113258. doi: 10.1016/j.ejca.2023.113258. Epub 2023 Jul 27. Eur J Cancer. 2023. PMID: 37660438 Free article. Clinical Trial.
161 results